The Role of Granulocytes Following Intravesical BCG Prophylaxis

European Urology

Volumn 51, Issue 6, 2007, Pages 1589-1599

  Siracusano, Salvatore ^a   Vita, Francesca ^a   Abbate, Rita ^a   Ciciliato, Stefano ^a   Borelli, Violetta ^a   Bernabei, Massimiliano ^a   Zabucchi, Giuliano ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

BCG; Bladder cancer; Granulocyte; Immunotherapy

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER PREVENTION; CELL ACTIVATION; CELL ADHESION; CELL DAMAGE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EOSINOPHIL COUNT; GRANULOCYTE; GRANULOCYTE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICTURITION; NEUTROPHIL COUNT; PRIORITY JOURNAL; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; URINALYSIS; URINE CYTOLOGY; UROTHELIUM;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GRANULOCYTES; HUMANS; LUMINESCENCE; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 34247403479     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.11.045     Document Type: Article

References (43)

1. Morales A., Edinger D., and Bruce A.W. Intracavity bacillus Calmette Guérin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
2. Lamn D.L., Thor D.E., Harris S.C., Reyna J.A., Stogdill W.D., and Radwin H.M. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124 (1980) 38-40
3. de Boer E.C., de Jong W.H., van der Meijden A.P., et al. Leucocytes in urine after intravesical BCG treatment for superficial bladder cancer: a flow cytofluorimetric analysis. Urol Res 19 (1991) 45-50
4. Taniguchi K., Koga S., Nishikido M., et al. Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol 115 (1999) 131-135
5. Kaempfer R., Gerez L., Farbstein H., et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14 (1996) 1778-1786
6. Saint F., Patard J.J., Maille P., et al. T helper 1/2 lymphocyte urynary cytokine profiles in responding and non responding patients after 1 and 2 courses of bacillus Calmette-Guérin for superficial bladder cancer. J Urol 166 (2001) 2142-2147
7. Luo Y., Yamada H., Chen X., et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137 (2004) 24-34
8. Luo Y., Chen X., and O'Donnell M.A. Role of TH1 and TH2 cytokines in BCG-induced IFN-production: cytokine promotion and simulation of BCG effect. Cytokine 21 (2003) 17-26
9. Prescott S., James K., Hargreave T.B., Chisholm G.D., and Smyth J.F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147 (1992) 1636-1642
10. Shapiro A.W., Lijovetsky G., and Pode D. Changes of the mucosal architecture and urine cytology during BCG treatment. World J Urol 6 (1988) 61-64
11. Bohle A., Gerdes J., Ulmer A.J., Hofstetter A.G., and Flad H.D. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144 (1990) 53-58
12. el-Demiry M.I., Smith G., Ritchie A.W., et al. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol 60 (1987) 543-548
13. Kemp T.J., Ludwig A.T., Earel J.K., et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 106 (2005) 3474-3482
14. Ludwig A.T., Moore J.M., Luo Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guérin-induced antitumor activity. Cancer Res 64 (2004) 3386-3390
15. Kamohara H., Matsuyama W., Shimozato O., et al. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology 11 (2004) 186-194
16. Bäckhed F., Söderhäll M., Ekman P., Normark S., and Richter-Dahlfors A. Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. Cell Microbiol 3 (2001) 153-158
17. Heldwein K.A., Liang M.D., Andresen T.K., et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 74 (2003) 277-286
18. Miyazaki J., Kawai K., Oikawa T., et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling. BJU Int 97 (2006) 860-864
19. Alexandroff A.B., Jackson A.M., O'Donnell M.A., and James K. BCG immunotherapy of bladder cancer: 20 years on [review]. Lancet 353 (1999) 1689-1694
20. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer [review]. Apoptosis 9 (2004) 691-704
21. Bradford M.M. A rapid and sensitive method for the quantitation of micrograms quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
22. Lungarella G., Menegazzi R., Gardi C., et al. Identification of elastase in human eosinophils: immunolocalization, isolation, and partial characterization. Arch Biochem Biophys 292 (1992) 128-135
23. Menegazzi R., Zabucchi G., Knowles A., Cramer R., and Patriarca P. A new, one-step assay on whole cell suspensions for peroxidase secretion by human neutrophils and eosinophils. J Leukoc Biol 52 (1992) 619-624
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
25. Brochetta C., Perrotta M.G., Jeromin A., et al. Identification and subcellular localization of neuronal calcium sensor-1 (NCS-1) in human neutrophils and HL-60 cells. Inflammation 27 (2003) 361-372
26. Rajala P., Kaasinen E., Rintala E., et al. Cytostatic effect of different strains of bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res 20 (1992) 215-217
27. Sengeløv H., Follin P., Kjeldsen L., Lollike K., Dahlgren C., and Borregaard N. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. J Immunol 154 (1995) 4157-4165
28. Showell H.J., Freer R.J., Zigmond S.H., et al. The structure of synthetic peptides as chemotactic factors and inducers of lysosomal enzyme secretion for neutrophils. J Exp Med 143 (1976) 1154-1169
29. LeBouder E., Rey-Nores J.E., Rushmere N.K., et al. Soluble forms of Toll-like receptor (TLR-2) capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 171 (2003) 6680-6689
30. Huland E., and Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118 (1992) 463-467
31. McAveney K.M., Gomella L.G., and Lattime E.C. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 39 (1994) 401-406
32. de Boer E.C., Rooyakkers S.J., Schamhart D.H.J., de Reijke T.M., and Kurth K.-H. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol 48 (2005) 333-338
33. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
34. Mizutani Y., Nio Y., Fukumoto M., and Yoshida O. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69 (1992) 537-545
35. Bainton D.F. Developmental biology of neutrophils and eosinophils. In: Gallin J.I., and Snyderman R. (Eds). Inflammation: basic principles and clinical correlates. ed. 3 (1999), Lippincott Williams & Wilkins, Philadelphia 721-768
36. Rook A.W.G., and Bloom B.R. Tuberculosis: pathogenesis, protection and control. In: Bloom B.R. (Ed). Mechanism of pathogenesis in tuberculosis (1994), American Society for Microbiology, Washington, DC 485-501
37. Hang L., Haraoka M.W., Agace W., et al. Macrophage inflammatory protein-2 is required for neutrophil passage across the epithelial barrier of the infected urinary tract. J Immunol 162 (1999) 3037-3044
38. Godaly G., Bergsten G., Hang L., et al. Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. J Leukoc Biol 69 (2001) 899-906
39. Shimizu T., Yokota S., Takahashi S., et al. Membrane-anchored CD14 is important for induction of interleukin-8 by lipopolysaccharide and peptidoglycan in uroepithelial cells. Clin Diagn Lab Immunol 11 (2004) 969-976
40. Godaly G., Hang L., Frendeus B., and Svanborg C. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J Immunol 165 (2000) 5287-5294
41. Klebanoff S.J. Oxygen metabolites form phagocytes. In: Gallin J.I., and Snyderman R. (Eds). Inflammation: basic principles and clinical correlates. ed. 3 (1999), Lippincott Williams & Wilkins, Philadelphia 721-768
42. Elsbach P., Weiss J., and Levy O. Oxygen-independent antimicrobial systems of phagocytes. In: Gallin J.I., and Snyderman R. (Eds). Inflammation: basic principles and clinical correlates. ed. 3 (1999), Lippincott Williams & Wilkins, Philadelphia 801-817
43. Godaly G., and Young D.B. Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation. Cell Microbiol 7 (2005) 591-601